Current clinical recommendations provided by the 2016 European Society of Cardiology
(ESC) and 2017 American College of Cardiology (ACC)/American Heart Association …

Acute heart failure (AHF) episodes are marked by high rates of morbidity and mortality
during the episode and minimal advancements in its care. Multiple biomarker monitoring is …

Background Heart failure (HF) is a chronic and common condition with a rising prevalence,
especially in the elderly. Morbidity and mortality rates in people with HF are similar to those …

Abstract Purpose of Review Heart failure (HF) is one of the leading causes of cardiac
morbidity and mortality around the world. Our evolving understanding of the cellular and …

Background: Heart failure guidelines recommend up-titration of angiotensin-converting
enzyme (ACE) inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …

Heart failure (HF) represents a significant global health challenge, characterized by high
morbidity and mortality rates, and imposes considerable burdens on healthcare systems and …

Background Most heart failure (HF) risk scores have been derived from cohorts of stable HF
patients and may not incorporate up to date treatment regimens or deep phenotype …

Abstract Purpose of Review Biomarker-guided management of patients with chronic heart
failure with reduced ejection fraction (HFrEF) remains controversial. Recent Findings …